

# Arnold Ganser

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8861278/arnold-ganser-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

702  
papers

26,789  
citations

70  
h-index

155  
g-index

736  
ext. papers

31,457  
ext. citations

4.3  
avg, IF

6.31  
L-index

#	Paper	IF	Citations
702	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2209-2221	59.2	1999
701	Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. <i>Lancet, The</i> , <b>2004</b> , 364, 141-8	40	1803
700	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1909-18	59.2	1330
699	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 454-464	59.2	1067
698	Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 111-21	59.2	964
697	Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOW transfer to enhance ST-elevation infarct regeneration) trial. <i>Circulation</i> , <b>2006</b> , 113, 1287-94	16.7	826
696	Monitoring of bone marrow cell homing into the infarcted human myocardium. <i>Circulation</i> , <b>2005</b> , 111, 2198-202	16.7	788
695	Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 640-52	59.2	628
694	Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the Cancer and MDS Study Group. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1997-2006	2.2	419
693	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , <b>2012</b> , 119, 2114-21	2.2	411
692	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 489-500	21.7	400
691	Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 2424-37	7.6	352
690	Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. <i>Nature Genetics</i> , <b>2007</b> , 39, 99-105	36.3	352
689	Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. <i>Blood</i> , <b>2012</b> , 119, 3578-84	2.2	313
688	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , <b>2011</b> , 117, 2137-45	2.2	306
687	Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2709-16	2.2	297
686	Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. <i>Blood</i> , <b>2007</b> , 109, 4399-405	2.2	289

685	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. <i>Blood</i> , <b>2011</b> , 117, 2469-75	2.2	276
684	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. <i>Blood</i> , <b>2014</b> , 124, 3441-9	2.2	260
683	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1364-72	2.2	245
682	How I treat the acquired von Willebrand syndrome. <i>Blood</i> , <b>2011</b> , 117, 6777-85	2.2	239
681	Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. <i>European Heart Journal</i> , <b>2009</b> , 30, 2978-84	9.5	236
680	Specific inhibition of bcr-abl gene expression by small interfering RNA. <i>Blood</i> , <b>2003</b> , 101, 1566-9	2.2	234
679	Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2499-506	2.2	220
678	Tumor suppressor genes in normal and malignant hematopoiesis. <i>Oncogene</i> , <b>2002</b> , 21, 3475-95	9.2	209
677	Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2356-64	2.2	193
676	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , <b>2017</b> , 129, 1753-1762	2.2	189
675	High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2101-7	2.2	189
674	A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. <i>Haematologica</i> , <b>2012</b> , 97, 393-401	6.6	188
673	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 126, 319-27	2.2	185
672	Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2816-25	2.2	171
671	Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3890-8	2.2	167
670	Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. <i>European Heart Journal</i> , <b>2008</b> , 29, 2851-8	9.5	167
669	G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. <i>Blood</i> , <b>2003</b> , 102, 734-9	2.2	165
668	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , <b>2017</b> , 49, 332-340	36.3	155

667	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. <i>Haematologica</i> , <b>2010</b> , 95, 1668-74	6.6	155
666	Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. <i>Nucleic Acids Research</i> , <b>2007</b> , 35, e149	20.1	154
665	Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). <i>Hematology/Oncology Clinics of North America</i> , <b>2000</b> , 14, 1307-25, ix	3.1	148
664	Human $\Gamma$ cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. <i>Nature Immunology</i> , <b>2017</b> , 18, 393-401	19.1	146
663	Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. <i>Blood</i> , <b>2009</b> , 113, 4505-11	2.2	142
662	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , <b>2018</b> , 132, 1703-1713	2.2	142
661	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. <i>Blood</i> , <b>2019</b> , 133, 840-851	2.2	141
660	Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. <i>Nature Communications</i> , <b>2015</b> , 6, 6042	17.4	139
659	Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. <i>Leukemia Research</i> , <b>2010</b> , 34, 1143-50	2.7	136
658	The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 186, 199-207	16.6	136
657	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , <b>2013</b> , 121, 170-7	2.2	134
656	TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. <i>Oncogene</i> , <b>1999</b> , 18, 1209-17	9.2	131
655	Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2007</b> , 109, 5511-9	2.2	130
654	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , <b>2014</b> , 123, 914-20	2.2	129
653	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , <b>2013</b> , 121, 4769-77	2.2	129
652	Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 11299-304	11.5	126
651	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. <i>Blood</i> , <b>2012</b> , 119, 551-8	2.2	120
650	Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5183-91	2.2	119

649	Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. <i>Nature Medicine</i> , <b>2015</b> , 21, 140-9	50.5	117
648	Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. <i>European Journal of Immunology</i> , <b>2009</b> , 39, 3091-6	6.1	112
647	Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3724-9	2.2	110
646	Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 4413-22	2.2	108
645	Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). <i>Blood</i> , <b>2006</b> , 107, 3279-87	2.2	103
644	Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2004</b> , 103, 3603-5	2.2	100
643	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , <b>2017</b> , 8, 73483-73500	3.3	99
642	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized	2.2	93
641	IFN- $\gamma$ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. <i>Journal of Immunology</i> , <b>2012</b> , 189, 2890-6	5.3	89
640	Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. <i>Genes Chromosomes and Cancer</i> , <b>2012</b> , 51, 689-95	5	88
639	Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. <i>Blood</i> , <b>2011</b> , 117, 4338-48	2.2	81
638	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , <b>2011</b> , 117, 4561-8	2.2	81
637	Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 529-33	2.2	80
636	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , <b>2017</b> , 1, 86-89	7.8	78
635	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , <b>2013</b> , 121, 1935-43	2.2	77
634	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. <i>Annals of Hematology</i> , <b>2016</b> , 95, 191-9	3	73
633	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 694-700	4.5	71
632	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , <b>2021</b> , 138, 350-353	2.2	69

631	Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. <i>Cancer Cell</i> , <b>2011</b> , 20, 39-52	24.3	68
630	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , <b>2015</b> , 100, 324-30	6.6	67
629	First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. <i>Disaster Medicine and Public Health Preparedness</i> , <b>2011</b> , 5, 202-12	2.8	67
628	Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. <i>Blood</i> , <b>2002</b> , 99, 709-12	2.2	67
627	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1095-1101	4.7	65
626	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , <b>2020</b> , 57, 102885	8.8	65
625	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , <b>2019</b> , 134, 892-899	2.2	64
624	Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. <i>European Heart Journal</i> , <b>2017</b> , 38, 2936-2943	9.5	64
623	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , <b>2019</b> , 10, 2031	17.4	63
622	Modulation of Gene Expression by Lentiviral-Mediated Delivery of Small Interfering RNA. <i>Cell Cycle</i> , <b>2003</b> , 2, 250-256	4.7	63
621	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , <b>2019</b> , 133, 1140-1151	2.2	61
620	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , <b>2012</b> , 119, e67-75	2.2	59
619	Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. <i>Haematologica</i> , <b>2005</b> , 90, 1484-92	6.6	59
618	Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. <i>Haematologica</i> , <b>2011</b> , 96, 1870-3	6.6	57
617	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. <i>Haematologica</i> , <b>2008</b> , 93, 826-33	6.6	57
616	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. <i>Blood</i> , <b>2015</b> , 126, 1885-92; quiz 1970	2.2	56
615	Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. <i>Nature Medicine</i> , <b>2012</b> , 18, 1550-9	50.5	56
614	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 238-246	4.5	54

613	Human regulatory T cells in allogeneic stem cell transplantation. <i>Blood</i> , <b>2011</b> , 118, e82-92	2.2	54
612	Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. <i>Disaster Medicine and Public Health Preparedness</i> , <b>2011</b> , 5, 183-201	2.8	54
611	Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. <i>British Journal of Haematology</i> , <b>1999</b> , 107, 80-5	4.5	54
610	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. <i>Leukemia</i> , <b>2018</b> , 32, 1621-1630	10.7	53
609	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , <b>2020</b> , 135, 371-380	2.2	53
608	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1931-1942	2.2	52
607	Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 72-8	4.5	51
606	A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002375	7.6	49
605	Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7501-7501	2.2	49
604	Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 682-9	2.2	47
603	Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 103-110	4.7	46
602	Comparative genomic hybridization in the investigation of myeloid leukemias. <i>Genes Chromosomes and Cancer</i> , <b>1995</b> , 12, 193-200	5	46
601	Clonal Hematopoiesis of Indeterminate Potential. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2016</b> , 113, 317-22	2.5	46
600	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , <b>2019</b> , 134, 1608-1618	2.2	45
599	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. <i>Annals of Hematology</i> , <b>2013</b> , 92, 747-58	3	44
598	The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia. <i>Annals of Internal Medicine</i> , <b>1989</b> , 111, 887-92	8	43
597	Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 52-60	3.8	42
596	A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting. <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 742-51	7.6	42

595	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 237-245	6.6	42
594	Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. <i>Haematologica</i> , <b>2002</b> , 87, 643-51	6.6	42
593	Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity. <i>Experimental Hematology</i> , <b>2011</b> , 39, 1152-60	3.1	41
592	Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 14304-13	5.4	41
591	HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 187-96	4.7	41
590	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , <b>2014</b> , 93, 2001-10	3	40
589	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2013</b> , 92, 315-23	3	40
588	Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. <i>Journal of Immunology</i> , <b>2014</b> , 192, 4636-47	5.3	40
587	Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells. <i>Annals of Hematology</i> , <b>2011</b> , 90, 213-8	3	40
586	Recovery and composition of microparticles after snap-freezing depends on thawing temperature. <i>Blood Coagulation and Fibrinolysis</i> , <b>2009</b> , 20, 52-6	1	40
585	High-affinity neurotrophin receptors and ligands promote leukemogenesis. <i>Blood</i> , <b>2009</b> , 113, 2028-37	2.2	40
584	Legionnaires' disease in immunocompromised patients: a case report of Legionella longbeachae pneumonia and review of the literature. <i>Journal of Medical Microbiology</i> , <b>2008</b> , 57, 384-387	3.2	40
583	Hematopoietic growth factors in the treatment of acquired bone marrow failure states. <i>Seminars in Hematology</i> , <b>2007</b> , 44, 138-47	4	40
582	Treatment of Relapsed Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , <b>2020</b> , 21, 66	5.4	39
581	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <i>Haematologica</i> , <b>2007</b> , 92, 763-70	6.6	39
580	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1361-1372	3	38
579	Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop. <i>Stem Cells</i> , <b>2009</b> , 27, 1205-11	5.8	38
578	Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells. <i>Human Gene Therapy</i> , <b>1998</b> , 9, 1561-70	4.8	38



577	Haploidentical unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , <b>2019</b> , 104, 524-532	6.6	38
576	Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. <i>Expert Review of Proteomics</i> , <b>2005</b> , 2, 639-47	4.2	37
575	Genetic characterization of acquired aplastic anemia by targeted sequencing. <i>Haematologica</i> , <b>2014</b> , 99, e165-7	6.6	36
574	Allogeneic Stem Cell Transplantation for Patients Age $\geq$ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 44-52	4.7	36
573	Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 413-9	4.5	36
572	Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2005</b> , 130, 912-25	4.5	36
571	Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. <i>American Journal of Clinical Pathology</i> , <b>2001</b> , 116, 567-74	1.9	36
570	BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , <b>2014</b> , 124, 379-379	2.2	36
569	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. <i>Haematologica</i> , <b>2011</b> , 96, 681-6	6.6	35
568	Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA. <i>Molecular Therapy</i> , <b>2001</b> , 4, 454-60	11.7	35
567	Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 623-632	2.2	35
566	Detection and quantification of CFBF/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. <i>Genes Chromosomes and Cancer</i> , <b>2001</b> , 30, 342-8	5	33
565	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , <b>2016</b> , 101, 256-62	6.6	33
564	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age $>$ 69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1975-1983	4.7	32
563	Cutaneous side effects of new antitumor drugs: clinical features and management. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2012</b> , 109, 133-40	2.5	32
562	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , <b>2012</b> , 91, 1221-33	3	32
561	IL-3 in the clinic. <i>Stem Cells</i> , <b>1997</b> , 15, 327-33	5.8	32
560	Incidence of lineage promiscuity in acute myeloblastic leukemia: diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement analysis and immunological phenotyping. <i>Leukemia Research</i> , <b>1988</b> , 12, 887-95	2.7	32

559	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1905-1918	3	31
558	Chromothripsis is linked to alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. <i>Haematologica</i> , <b>2018</b> , 103, e17-e20	6.6	31
557	Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. <i>Haematologica</i> , <b>2013</b> , 98, 1045-8	6.6	30
556	Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. <i>Leukemia Research</i> , <b>2004</b> , 28, 1069-74	2.7	30
555	<i>Candida kefyr</i> as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1365-6	11.6	30
554	Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3. <i>British Journal of Haematology</i> , <b>1993</b> , 84, 749-51	4.5	30
553	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , <b>2015</b> , 126, 322-322	2.2	30
552	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2x2, Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 257-270	2.2	30
551	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , <b>2020</b> , 136, 3041-3050	2.2	30
550	Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. <i>Liver International</i> , <b>2006</b> , 26, 173-81	7.9	29
549	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1406-1414	4.7	28
548	Isotype controls in phenotyping and quantification of microparticles: a major source of error and how to evade it. <i>Thrombosis Research</i> , <b>2008</b> , 122, 691-700	8.2	28
547	T cell receptor gamma chain variable gene rearrangements in acute lymphoblastic leukemias of T and B lineage. <i>European Journal of Immunology</i> , <b>1987</b> , 17, 1593-7	6.1	28
546	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1114-1125	4.4	28
545	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. <i>Rna</i> , <b>2016</b> , 22, 1535-49	5.8	28
544	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 130	22.4	27
543	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 278-284	4.7	27
542	Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. <i>PLoS ONE</i> , <b>2012</b> , 7, e50248	3.7	27

541	Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. <i>Haematologica</i> , <b>2013</b> , 98, 518-25	6.6	27
540	Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. <i>Annals of Hematology</i> , <b>2010</b> , 89, 841-50	3	27
539	Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. <i>Seminars in Hematology</i> , <b>2007</b> , 44, 148-56	4	27
538	High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3295-300	1.9	26
537	Morphology and quantitative composition of hematopoietic cells in murine bone marrow and spleen of healthy subjects. <i>Annals of Hematology</i> , <b>2013</b> , 92, 587-94	3	26
536	BCR-ABL affects STAT5A and STAT5B differentially. <i>PLoS ONE</i> , <b>2014</b> , 9, e97243	3.7	26
535	The neutrophil recombinatorial TCR-like immune receptor is expressed across the entire human life span but repertoire diversity declines in old age. <i>Biochemical and Biophysical Research Communications</i> , <b>2012</b> , 419, 309-15	3.4	26
534	Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 22, 287-94	1.9	26
533	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , <b>2020</b> , 34, 914-918	10.7	26
532	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1347-56	3	24
531	Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. <i>European Journal of Haematology</i> , <b>2012</b> , 89, 214-9	3.8	24
530	Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. <i>Annals of Hematology</i> , <b>2011</b> , 90, 1047-58	3	24
529	Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. <i>Human Gene Therapy</i> , <b>2011</b> , 22, 829-41	4.8	24
528	Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. <i>Liver</i> , <b>2002</b> , 22, 114-20		24
527	Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. <i>Transplantation</i> , <b>2000</b> , 70, 688-90	1.8	24
526	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 89	22.4	24
525	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , <b>2018</b> , 2, 2127-2135	7.8	24
524	Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2013</b> , 92, 1079-90	3	23

523	Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. <i>European Journal of Haematology</i> , <b>2014</b> , 93, 429-38	3.8	23
522	Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. <i>Annals of Hematology</i> , <b>2005</b> , 84, 389-94	3	23
521	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1050-1058	4.4	23
520	Therapy-related myeloid neoplasms. <i>Current Opinion in Hematology</i> , <b>2017</b> , 24, 152-158	3.3	22
519	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. <i>Haematologica</i> , <b>2014</b> , 99, 1456-64	6.6	22
518	High Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , <b>2015</b> , 126, 2302-6	2.2	22
517	Differential quantitation of alternatively spliced messenger RNAs using isoform-specific real-time RT-PCR. <i>Analytical Biochemistry</i> , <b>1999</b> , 269, 210-3	3.1	22
516	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , <b>2020</b> , 4, 2073-2083	7.8	21
515	Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application. <i>PLoS ONE</i> , <b>2012</b> , 7, e51644	3.7	21
514	Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia. <i>International Journal of Hematology</i> , <b>2008</b> , 87, 414-421	2.3	21
513	Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. <i>European Journal of Haematology</i> , <b>2005</b> , 75, 68-72	3.8	21
512	Colony-stimulating factors in the management of neutropenia and its complications. <i>Annals of Hematology</i> , <b>2005</b> , 84, 697-708	3	21
511	Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. <i>Human Gene Therapy</i> , <b>2013</b> , 24, 220-37	4.8	20
510	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , <b>2017</b> , 171, 431-439	4.5	20
509	Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies. <i>Annals of Hematology</i> , <b>2009</b> , 88, 907-12	3.2	20
508	Acquired haemophilia caused by non-haemophilic factor VIII gene variants. <i>Annals of Hematology</i> , <b>2010</b> , 89, 607-12	3	20
507	Synthesis and properties of hammerhead ribozymes stabilized against nucleases by different 2'-modifications: methoxyethoxy-, fluoro- and amino groups. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1997</b> , 7, 1791-1796	2.9	20
506	Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. <i>Xenotransplantation</i> , <b>2008</b> , 15, 46-55	2.8	20

505	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , <b>2008</b> , 93, 1219-26	6.6	20
504	Cytogenetic studies in chronic myeloproliferative disorders. <i>Acta Haematologica</i> , <b>1983</b> , 69, 145-51	2.7	20
503	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). <i>Annals of Hematology</i> , <b>2015</b> , 94, 2003-13	3	19
502	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. <i>Journal of Critical Care</i> , <b>2020</b> , 57, 124-129	4	19
501	Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1457-1465	4.4	19
500	Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients. <i>Intensive Care Medicine</i> , <b>2018</b> , 44, 1483-1492	14.5	19
499	Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2015</b> , 1, 14060	6.4	19
498	Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor. <i>PLoS ONE</i> , <b>2013</b> , 8, e77925	3.7	19
497	ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPbeta-LIP expression and LIP/LAP ratio by different signalling modules. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 777-90	4.5	19
496	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , <b>2021</b> , 137, 3093-3104	2.2	19
495	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , <b>2016</b> , 101, 839-45	6.6	19
494	Human Effector Memory T Helper Cells Engage with Mouse Macrophages and Cause Graft-versus-Host-Like Pathology in Skin of Humanized Mice Used in a Nonclinical Immunization Study. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 1380-1398	5.8	18
493	TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. <i>Genes Chromosomes and Cancer</i> , <b>2014</b> , 53, 824-32	5	18
492	Bone marrow findings after treatment with recombinant human interleukin-3. <i>American Journal of Clinical Pathology</i> , <b>1991</b> , 95, 355-62	1.9	18
491	Possible Impact of Cytomegalovirus-Specific CD8 T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1046-1053	4.7	17
490	In vitro improvement of bone marrow-derived hematopoietic colony formation in HIV-positive patients by alpha-D-tocopherol and erythropoietin. <i>European Journal of Haematology</i> , <b>1994</b> , 53, 201-6	3.8	17
489	Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.. <i>Blood</i> , <b>2007</b> , 110, 12-12	2.2	17
488	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , <b>2019</b> , 134, 951-959	2.2	16

487	Value of proteomics applied to the follow-up in stem cell transplantation. <i>Annals of Hematology</i> , <b>2006</b> , 85, 205-11	3	16
486	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. <i>World Journal of Urology</i> , <b>2010</b> , 28, 391-8	4	15
485	Paroxysmal nocturnal hemoglobinuria: Differential gene expression of EGR-1 and TAXREB107. <i>Experimental Hematology</i> , <b>2002</b> , 30, 18-25	3.1	15
484	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , <b>2016</b> , 128, 449-449	2.2	15
483	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , <b>2021</b> , 35, 2539-2551	10.7	15
482	Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. <i>Current Cancer Drug Targets</i> , <b>2016</b> , 16, 818-828	2.8	15
481	Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. <i>Annals of Hematology</i> , <b>2019</b> , 98, 897-907	3	15
480	Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34 Cells. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2734	8.4	15
479	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 26	7	14
478	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 809-816	7.1	14
477	Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 240	8.5	14
476	Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation. <i>Hematology</i> , <b>2012</b> , 11, 1881-8	6.6	14
475	Risks and benefits of erythropoiesis-stimulating agents in cancer management. <i>Seminars in Hematology</i> , <b>2007</b> , 44, 157-65	4	14
474	Plasma P-selectin levels are elevated in patients with chronic liver disease. <i>Blood Coagulation and Fibrinolysis</i> , <b>2003</b> , 14, 319-25	1	14
473	Inhibition of granulocyte-macrophage colony-stimulating factor receptor function by a splice variant of the common beta-receptor subunit. <i>Blood</i> , <b>2001</b> , 98, 2689-96	2.2	14
472	FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 188, e11-e15	4.5	14
471	CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 504-524	6.4	14
470	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 686-695	10.7	14

469	Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 531-539	4.4	13
468	Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 149-61	5.5	13
467	Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD.Rag1 <sup>-/-</sup> .IL-2rβ <sup>-/-</sup> mice. <i>Human Gene Therapy</i> , <b>2011</b> , 22, 1209-24	4.8	13
466	Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML. <i>Annals of Hematology</i> , <b>2010</b> , 89, 459-67	3	13
465	Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation. <i>International Journal of Hematology</i> , <b>2006</b> , 83, 271-4	2.3	13
464	Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. <i>Liver</i> , <b>2002</b> , 22, 205-12		13
463	Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.. <i>Blood</i> , <b>2005</b> , 106, 172-172	2.2	13
462	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , <b>2020</b> , 4, 4945-4954	7.8	13
461	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. <i>Haematologica</i> , <b>2021</b> , 106, 565-573	6.6	13
460	Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. <i>Frontiers in Pharmacology</i> , <b>2015</b> , 6, 76	5.6	12
459	Successful use of extracorporeal membrane oxygenation during induction chemotherapy in a patient with mediastinal tumor mass of a T lymphoblastic lymphoma. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1719-21	3	12
458	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , <b>2015</b> , 100, e122-4	6.6	12
457	Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. <i>Annals of Hematology</i> , <b>2011</b> , 90, 273-81	3	12
456	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.. <i>Blood</i> , <b>2005</b> , 106, 1852-1852	2.2	12
455	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia [Results of the AMLSG 07-04 Randomized Treatment Trial. <i>Blood</i> , <b>2011</b> , 118, 80-80	2.2	12
454	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. <i>Blood</i> , <b>2012</b> , 120, 6-6	2.2	12
453	Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2008</b> , 105, 232-7	2.5	12
452	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 65	22.4	12

451	Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation. <i>Journal of Immunology</i> , <b>2017</b> , 199, 792-805	5.3	11
450	Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia. <i>Current Opinion in Hematology</i> , <b>1997</b> , 4, 191-5	3.3	11
449	The AML1/MTG8 Fusion Transcript in t(8;21) Positive AML and its Implication for the Detection of Minimal Residual Disease. <i>Hematology</i> , <b>2000</b> , 5, 369-81	2.2	11
448	Clinical use of hematopoietic growth factors. <i>Current Opinion in Oncology</i> , <b>1996</b> , 8, 265-9	4.2	11
447	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study.. <i>Blood</i> , <b>2007</b> , 110, 300-300	2.2	11
446	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , <b>2016</b> , 128, 589-589	2.2	11
445	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , <b>2020</b> , 4, 6342-6352	7.8	11
444	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1551-1560	3	10
443	Leukemogenic potency of the novel FLT3-N676K mutant. <i>Annals of Hematology</i> , <b>2016</b> , 95, 783-91	3	10
442	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2251-2260	4.7	10
441	Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119595	3.7	10
440	Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 518-9	4.5	10
439	Delayed distant spinal metastasis in thymomas. <i>Spine</i> , <b>2013</b> , 38, E1709-13	3.3	10
438	Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>1997</b> , 12, 143-7	3.9	10
437	Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. <i>Leukemia Research</i> , <b>2002</b> , 26, 1073-5	2.7	10
436	Platelet glycoprotein expression in patients with myelodysplastic syndrome. <i>Thrombosis Research</i> , <b>2000</b> , 100, 27-34	8.2	10
435	Megakaryocytic cells in mixed haemopoietic colonies (CFU-GEMM) from the peripheral blood of normal individuals. <i>British Journal of Haematology</i> , <b>1985</b> , 59, 627-33	4.5	10
434	Gene Mutations as Predictive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. <i>Blood</i> , <b>2006</b> , 108, 4-4	2.2	10



433	Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T <sub>H</sub> Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 521-539	5.8	10
432	miR-181a Expression in Donor T Cells Modulates Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation. <i>Journal of Immunology</i> , <b>2016</b> , 196, 3927-34	5.3	9
431	DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders. <i>Laboratory Animals</i> , <b>2009</b> , 43, 390-3	2.6	9
430	Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. <i>World Journal of Urology</i> , <b>2007</b> , 25, 59-72	4	9
429	Expression of the p75 neurotrophin receptor in acute leukaemia. <i>British Journal of Haematology</i> , <b>2005</b> , 131, 67-70	4.5	9
428	HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2001</b> , 16, 401-9	3.9	9
427	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AML5G). <i>Blood</i> , <b>2016</b> , 128, 1207-1207	2.2	9
426	Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1717-1725	2.2	9
425	Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 431-438	7.1	9
424	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. <i>Leukemia</i> , <b>2020</b> , 34, 416-426	10.7	9
423	Clinical impact of expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , <b>2017</b> , 1, 1807-1814	7.1	8
422	Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?. <i>Transplantation</i> , <b>2014</b> , 98, 569-77	1.8	8
421	Evaluation of tissue factor bearing microparticles as biomarkers in allogeneic stem-cell transplantation. <i>Transplantation</i> , <b>2011</b> , 92, 351-8	1.8	8
420	Intramedullary spinal cord implantation of human CD34+ umbilical cord-derived cells in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , <b>2011</b> , 12, 325-30		8
419	Sustained decrease of peripheral lymphocytes after allogeneic blood stem cell aphereses. <i>British Journal of Haematology</i> , <b>1998</b> , 100, 695-7	4.5	8
418	Recombinant human erythropoietin in the treatment of nonrenal anemia. <i>Annals of Hematology</i> , <b>2006</b> , 85, 69-78	3	8
417	Clinical results with recombinant human interleukin-3. <i>Cancer Investigation</i> , <b>1993</b> , 11, 212-8	2.1	8
416	Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 73871-73883	3.3	8

415	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
414	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , <b>2021</b> , 5, 2294-2304	7.8	8
413	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allograft: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 451-457	4.7	8
412	Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. <i>Hematological Oncology</i> , <b>2020</b> , 38, 244-256	1.3	8
411	Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 979-983	4.5	7
410	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Transfusion</i> , <b>2019</b> , 59, 11-18	7	7
409	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 2951-2963	10.7	7
408	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN- $\gamma$ and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1891-1899	7.4	7
407	ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 208-215	4.5	7
406	Activation of TRKB receptor in murine hematopoietic stem/progenitor cells induced mastocytosis. <i>Blood</i> , <b>2014</b> , 124, 1196-7	2.2	7
405	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2014</b> , 93, 193-202	3	7
404	Erythropoietin in cancer-related anemia. <i>Current Opinion in Oncology</i> , <b>2008</b> , 20, 685-9	4.2	7
403	Classical Hodgkin's lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. <i>Tumor Biology</i> , <b>2006</b> , 27, 329-33	2.9	7
402	Functional analysis of a single chain chimeric alpha/beta-granulocyte-macrophage colony-stimulating factor receptor. Importance of a glutamate residue in the transmembrane region. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 33064-71	5.4	7
401	A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia. <i>Blood</i> , <b>2014</b> , 124, 3598-3598	2.2	7
400	Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) 7 Year Updated Results from the StiL NHL1 Study. <i>Blood</i> , <b>2014</b> , 124, 4407-4407	2.2	7
399	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3744-3744	2.2	7
398	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. <i>Blood</i> , <b>2016</b> , 128, 745-745	2.2	7

397	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183828	3.7	7
396	Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. <i>Current Opinion in Hematology</i> , <b>1995</b> , 2, 204-9	3.3	7
395	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. <i>Leukemia</i> , <b>2021</b> , 35, 1301-1316	10.7	7
394	Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. <i>PLoS ONE</i> , <b>2019</b> , 14, e0213739	3.7	6
393	Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow</i>	4.7	6
392	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 280-290.e3	3.3	6
391	Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1127-35	7	6
390	Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 488-90	4.5	6
389	Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications. <i>Blood</i> , <b>2010</b> , 116, 909-909	3.2	6
388	Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.. <i>Blood</i> , <b>2012</b> , 120, 2608-2608	2.2	6
387	Tumor cell-based vaccination in renal cell carcinoma: rationale, approaches, and recent clinical development. <i>Current Drug Targets</i> , <b>2002</b> , 3, 401-8	3	6
386	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes. <i>Haematologica</i> , <b>2016</b> , 101, e177-81	6.6	6
385	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 1313-1323	10.7	6
384	Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. <i>Leukemia Research</i> , <b>2017</b> , 62, 84-90	2.7	5
383	The stem cell zinc finger 1 (SZF1)/ZNF589 protein has a human-specific evolutionary nucleotide DNA change and acts as a regulator of cell viability in the hematopoietic system. <i>Experimental Hematology</i> , <b>2016</b> , 44, 257-68	3.1	5
382	Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2014</b> , 93, 977-82	3	5
381	Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1367-81	4.9	5
380	Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 741-5	4.7	5

379	Cytological characterization of murine bone marrow and spleen hematopoietic compartments for improved assessment of toxicity in preclinical gene marking models. <i>Annals of Hematology</i> , <b>2013</b> , 92, 595-604	3	5
378	P-selectin glycoprotein ligand-1 positive microparticles in allogeneic stem cell transplantation of hematologic malignancies. <i>Experimental Hematology</i> , <b>2011</b> , 39, 1047-55	3.1	5
377	Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives. <i>Frontiers of Medicine in China</i> , <b>2010</b> , 4, 356-62		5
376	Competitive cytokeratin 19 RT-PCR for quantification of breast cancer cells in blood cell suspensions. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2000</b> , 9, 275-84		5
375	CFU-GM: CFU-mix ratio in the peripheral blood and bone marrow and its importance in autologous transplantation of circulating stem cells. <i>British Journal of Haematology</i> , <b>1986</b> , 64, 628-9	4.5	5
374	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. <i>Blood</i> , <b>2018</b> , 132, 81-81	2.2	5
373	Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.. <i>Blood</i> , <b>2004</b> , 104, 145-145	2.2	5
372	Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®). <i>Blood</i> , <b>2008</b> , 112, 1307-1307	2.2	5
371	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia [Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , <b>2014</b> , 124, 12-12	2.2	5
370	Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results From the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214). <i>Blood</i> , <b>2014</b> , 124, 3052-3052	2.2	5
369	Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 912-912	2.2	5
368	VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>PLoS ONE</i> , <b>2017</b> , 12, e0168096	3.7	5
367	Hepatosplenic candidiasis in patients with acute leukaemia. <i>British Journal of Haematology</i> , <b>2000</b> , 109, 672	4.5	5
366	Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. <i>Stem Cells</i> , <b>2016</b> , 34, 797-9	5.8	5
365	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 224-232	4.4	5
364	F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Annals of Nuclear Medicine</i> , <b>2021</b> , 35, 132-138	2.5	5
363	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. <i>Annals of Hematology</i> , <b>2017</b> , 96, 895-904	3	4
362	Expression of the ETS transcription factor GABPBs positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro. <i>Experimental Hematology</i> , <b>2015</b> , 43, 880-90	3.1	4

361	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2020</b> , 190, e169-e173	4.5	4
360	Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models. <i>Annals of Hematology</i> , <b>2011</b> , 90, 283-92	3	4
359	Reply to I.H.I.M. Hollink et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e527-e528	2.2	4
358	Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors. <i>BioDrugs</i> , <b>1998</b> , 10, 97-109	7.9	4
357	Comparative evaluation of commonly used clones and fluorochrome conjugates of monoclonal antibodies for CD34 antigen detection. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>1999</b> , 8, 547-59		4
356	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. <i>Blood</i> , <b>2018</b> , 132, 720-720	2.2	4
355	Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. <i>Blood</i> , <b>2006</b> , 108, 433-433	2.2	4
354	Satisfaction and Adherence Significantly Improves in Patients with $\beta$ -Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade <sup>®</sup> ). <i>Blood</i> , <b>2008</b> , 112, 1306-1306	2.2	4
353	Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). <i>Blood</i> , <b>2012</b> , 120, 1483-1483	2.2	4
352	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i>	4.7	4
351	Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. <i>Cancer Medicine</i> , <b>2020</b> , 9, 8386-8396	4.8	4
350	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225977	3.7	4
349	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 1294-1305	6.6	4
348	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , <b>2021</b> ,	10.7	4
347	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. <i>Annals of Hematology</i> , <b>2017</b> , 96, 887-894	3	3
346	Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin- $\alpha$ during Acute Graft-versus-Host Disease of the Liver. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 2069-2078	4.7	3
345	Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party. <i>Haematologica</i> , <b>2020</b> , 105, 1977-1983	6.6	3
344	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , <b>2020</b> , 10, 10315	4.9	3

343	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 586	8.4	3
342	Quantification of transforming capacity and cooperation of defined genetic alterations in myeloid malignancies. <i>Experimental Hematology</i> , <b>2010</b> , 38, 11-9	3.1	3
341	Persistent aplasia after chemotherapy for acute myeloid leukaemia treated with stem cell transplantation from a matched unrelated donor after dose-reduced conditioning. <i>British Journal of Haematology</i> , <b>2002</b> , 118, 442-4	4.5	3
340	Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. <i>Experimental Hematology</i> , <b>2005</b> , 33, 804-10	3.1	3
339	Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2001</b> , 10, 863-71		3
338	Analysis of the nuclear distribution of the translocation t(8;21)-derived fusion protein AML1/ETO by confocal laser scanning microscopy. <i>Journal of Hematotherapy and Stem Cell Research</i> , <b>2002</b> , 11, 401-8		3
337	A comparative review of methods for T cell depletion in the prophylaxis of graft-versus-host disease. <i>BioDrugs</i> , <b>1998</b> , 9, 105-23	7.9	3
336	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , <b>2018</b> , 132, 1501-1501	2.2	3
335	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , <b>2018</b> , 132, 435-435	2.2	3
334	Hemostatic Alterations in Patients Undergoing Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , <b>2004</b> , 104, 985-985	2.2	3
333	Long Term Remission in Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) with Rituximab Consolidation after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Extended Follow-Up of a Multicenter Phase II Study.. <i>Blood</i> , <b>2005</b> , 106, 2078-2078	2.2	3
332	The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis.. <i>Blood</i> , <b>2007</b> , 110, 761-761	2.2	3
331	TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome.. <i>Blood</i> , <b>2011</b> , 118, 3558-3558	2.2	3
330	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The AMLSG 16-10 Trial. <i>Blood</i> , <b>2018</b> , 132, 1502-1502	2.2	3
329	Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group. <i>Blood</i> , <b>2013</b> , 122, 1452-1452	2.2	3
328	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). <i>Blood</i> , <b>2015</b> , 126, 226-226	2.2	3
327	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 282-294	7.1	3
326	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3

325	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 592-601	4.5	3
324	Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. <i>Blood</i> , <b>2021</b> , 137, 2657-2661	2.2	3
323	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , <b>2020</b> , 105, 414-423	6.6	3
322	miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204942	3.7	3
321	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	3
320	Cardiac surgery in a patient with paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> , <b>2002</b> , 87, ECR296.6		3
319	The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 89, 847-52	7	3
318	Key Data Elements in Myeloid Leukemia. <i>Studies in Health Technology and Informatics</i> , <b>2016</b> , 228, 282-6	0.5	3
317	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. <i>Acta Radiologica Open</i> , <b>2017</b> , 6, 2058460117694216	1.2	2
316	Secondary AML Is an Independent Risk Factor for Outcome after SCT in First Complete Remission - a Registry-Based Comparison to De Novo AML on Behalf of the EBMT Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, S11	4.7	2
315	Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation. <i>Annals of Hematology</i> , <b>2009</b> , 88, 275-7	3	2
314	Mixed megakaryocytic-granulocytic differentiation during diffusion chamber culture of peripheral blast cells from the blast crisis of chronic myelocytic leukemia. <i>Leukemia Research</i> , <b>1985</b> , 9, 1031-41	2.7	2
313	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.. <i>Neurological Research and Practice</i> , <b>2022</b> , 4, 1	3.2	2
312	Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3-ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.. <i>Blood</i> , <b>2005</b> , 106, 2353-2353	2.2	2
311	Prognosis of Adult Patients $\geq$ 60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups.. <i>Blood</i> , <b>2005</b> , 106, 2360-2360	2.2	2
310	Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.. <i>Blood</i> , <b>2005</b> , 106, 2800-2800	2.2	2
309	Prognosis of Adult Patients $\geq$ 60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.. <i>Blood</i> , <b>2006</b> , 108, 16-16	2.2	2
308	Priming with Granulocyte-Colony Stimulating Factor Did Not Improve Outcome in a Randomized Study of Elderly Acute Myeloid Leukemia but Increased Induction Mortality.. <i>Blood</i> , <b>2006</b> , 108, 1980-1980	2.2	2

307	Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial.. <i>Blood</i> , <b>2006</b> , 108, 2020-2020	2.2	2
306	Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99.. <i>Blood</i> , <b>2007</b> , 110, 1461-1461	2.2	2
305	Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).. <i>Blood</i> , <b>2007</b> , 110, 364-364	2.2	2
304	Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?. <i>Blood</i> , <b>2008</b> , 112, 343-343	2.2	2
303	Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial. <i>Blood</i> , <b>2008</b> , 112, 439-439	2.2	2
302	In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.. <i>Blood</i> , <b>2009</b> , 114, 2632-2632	2.2	2
301	Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.. <i>Blood</i> , <b>2009</b> , 114, 4141-4141	2.2	2
300	Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).. <i>Blood</i> , <b>2009</b> , 114, 824-824	2.2	2
299	New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).. <i>Blood</i> , <b>2009</b> , 114, 90-90	2.2	2
298	No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 3090-3090	2.2	2
297	Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2012</b> , 120, 357-357	2.2	2
296	Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model. <i>Blood</i> , <b>2015</b> , 126, 1261-1261	2.2	2
295	The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Blood</i> , <b>2015</b> , 126, 3223-3223	2.2	2
294	Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 352-352	2.2	2
293	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. <i>Blood</i> , <b>2015</b> , 126, 803-803	2.2	2
292	TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response. <i>Blood</i> , <b>2016</b> , 128, 4605-4605		2
291	Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. <i>Oncotarget</i> , <b>2018</b> , 9, 2320-2328	3.3	2
290	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , <b>2020</b> , 13, 72	1.6	2



289	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , <b>2021</b> , 11, 8527	4.9	2
288	Induced dendritic cells co-expressing GM-CSF/IFN- $\gamma$ /WT1 priming T and B cells and automated manufacturing to boost GvL. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 21, 621-641	6.4	2
287	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AML SG 17-10 CIARA trial). <i>British Journal of Haematology</i> , <b>2018</b> , 183, 235-241	4.5	2
286	Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 2151-2160	4.2	2
285	Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 721738	8.4	2
284	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , <b>2021</b> , 185, 117-126	4.5	2
283	Focusing of the regulatory T-cell repertoire after allogeneic stem cell transplantation indicates protection from graft-host disease. <i>Haematologica</i> , <b>2019</b> , 104, e577-e580	6.6	1
282	Proteomics for hematopoietic stem cell transplantation. <i>Expert Review of Proteomics</i> , <b>2020</b> , 17, 201-206	4.2	1
281	High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?. <i>Annals of Hematology</i> , <b>2014</b> , 93, 1053-5	3	1
280	Genetic changes of miR-182 G106A: rather a polymorphism than a somatic mutation. <i>Annals of Hematology</i> , <b>2011</b> , 90, 1107-9	3	1
279	Detection of chronic systemic candida infection in leukaemia patients with febrile neutropenia: value of computer-assisted serial ultrasound documentation. <i>European Journal of Haematology</i> , <b>1998</b> , 60, 320-1	3.8	1
278	Reply to S. Masuda. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4593-4594	2.2	1
277	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. <i>World Journal of Urology</i> , <b>2010</b> , 28, 311-7	4	1
276	Safety, feasibility and therapeutic activity of intrapleural autologous lymphocyte conditioned medium followed by systemic recombinant interleukin-2 and interferon-alpha in a patient with malignant pleural mesothelioma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>1997</b> , 12, 141-2	3.9	1
275	Going from genes to proteins in myelodysplastic syndromes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 1109-10	11.5	1
274	Immunosuppressive treatment strategies in low-risk MDS. <i>Cancer Treatment Reviews</i> , <b>2007</b> , 33, S11-S14	14.4	1
273	Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient. <i>Oncology Research and Treatment</i> , <b>2005</b> , 28, 41-3	2.8	1
272	Cross-trial networking in AML: a step forward rather than corner cutting. <i>Leukemia Research</i> , <b>2004</b> , 28, 649-50	2.7	1

271	Elevated plasma levels of interleukin-1 receptor antagonist are associated with decreased cellular BCL-2 oncoprotein expression in B-chronic lymphocytic leukemia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>1998</b> , 13, 383-5	3.9	1
270	In vitro differentiation of a null-acute leukemia: T-lymphoid surface antigen expression associated with rearrangement in T-cell receptor beta chain variable genes. <i>Cancer Genetics and Cytogenetics</i> , <b>1987</b> , 28, 327-34		1
269	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 17-18	2.2	1
268	Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2018</b> , 132, 2166-2166	2.2	1
267	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , <b>2018</b> , 132, 1534-1534	2.2	1
266	Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapse after Allogeneic Stem Cell Transplantation. <i>Blood</i> , <b>2019</b> , 134, 184-184	2.2	1
265	Novel Molecular Pathogenesis and Therapeutic Target in Acute Erythroid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 914-914	2.2	1
264	Acquired Hemophilia Caused by Non-Hemophilic Factor VIII Gene Variants.. <i>Blood</i> , <b>2004</b> , 104, 3083-3083	2.2	1
263	Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.. <i>Blood</i> , <b>2004</b> , 104, 618-618	2.2	1
262	Valproic Acid Induces Cell Cycle Arrest and Differentiation of t(15;17) Positive Leukemic Cells Independent from ATRA Sensitivity and Has No Effect on CD34pos Cells.. <i>Blood</i> , <b>2005</b> , 106, 2834-2834	2.2	1
261	In CML, Marrow Fibrosis Relapses or Emerges in 5 - 6 % of Patients Per Year Independently Indicating Imatinib Failure and Shortened Survival Time of Patients.. <i>Blood</i> , <b>2006</b> , 108, 2195-2195	2.2	1
260	The Polycistronic miRNA Cluster miR-17-92 Is Over-Expressed in Early Phase Chronic Myeloid Leukemia (CML) CD34+ Cells.. <i>Blood</i> , <b>2006</b> , 108, 741-741	2.2	1
259	Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia - Results of a Retrospective Analysis in 368 Patients.. <i>Blood</i> , <b>2007</b> , 110, 172-172	2.2	1
258	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.. <i>Blood</i> , <b>2007</b> , 110, 47-47	2.2	1
257	RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG). <i>Blood</i> , <b>2008</b> , 112, 145-145	2.2	1
256	Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics [Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , <b>2008</b> , 112, 1971-1971	2.2	1
255	Extramedullary Acute Leukemias prior to and after Allogeneic Hematopoietic Stem Cell Transplantation: a Single Center Study.. <i>Blood</i> , <b>2008</b> , 112, 3262-3262	2.2	1
254	Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.. <i>Blood</i> , <b>2009</b> , 114, 1600-1600	2.2	1

253	MN1 Inhibits Myeloid Differentiation by Transcriptional Repression of EGR2. <i>Blood</i> , <b>2010</b> , 116, 229-229	2.2	1
252	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Blood</i> , <b>2011</b> , 118, 157-157	2.2	1
251	Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2011</b> , 118, 1709-1709	2.2	1
250	Deletion or Inhibition of Fc Gamma Receptor IIb (CD32) Prevents the Memory B Cell Response to Factor VIII in a Hemophilia A Mouse Model. <i>Blood</i> , <b>2011</b> , 118, 204-204	2.2	1
249	ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG. <i>Blood</i> , <b>2011</b> , 118, 412-412	2.2	1
248	DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. <i>Blood</i> , <b>2011</b> , 118, 415-415	2.2	1
247	Matched Pair Analysis of Cryopreserved Versus Fresh Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , <b>2011</b> , 118, 4529-4529	2.2	1
246	Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 1381-1381	2.2	1
245	Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322). <i>Blood</i> , <b>2012</b> , 120, 412-412	2.2	1
244	Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2014</b> , 124, 3171-3171	2.2	1
243	The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia. <i>Blood</i> , <b>2014</b> , 124, 366-366	2.2	1
242	ZRSR2 Mutations Cause Dysregulated RNA Splicing in MDS. <i>Blood</i> , <b>2014</b> , 124, 4609-4609	2.2	1
241	Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q. <i>Blood</i> , <b>2014</b> , 124, 4643-4643	2.2	1
240	Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2015</b> , 126, 1381-1381	2.2	1
239	Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG). <i>Blood</i> , <b>2015</b> , 126, 2585-2585	2.2	1
238	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2015</b> , 126, 2586-2586	2.2	1
237	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. <i>Blood</i> , <b>2015</b> , 126, 2891-2891	2.2	1
236	Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2015</b> , 126, 63-63	2.2	1

235	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. <i>Blood</i> , <b>2015</b> , 126, 85-85	2.2	1
234	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 337-337	2.2	1
233	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , <b>2016</b> , 128, 628-628	2.2	1
232	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 993-993	2.2	1
231	Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16070-e16070	2.2	1
230	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 610-610	2.2	1
229	Immunosuppressive therapy for myelodysplastic syndromes. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 3184-9	3.3	1
228	Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.. <i>Blood</i> , <b>2006</b> , 108, 2301-2301	2.2	1
227	RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.. <i>Blood</i> , <b>2006</b> , 108, 2303-2303	2.2	1
226	Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergrup.. <i>Blood</i> , <b>2007</b> , 110, 759-759 <sup>2,2</sup>	2.2	1
225	Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT. <i>Blood</i> , <b>2019</b> , 134, 701-701	2.2	1
224	Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial. <i>Blood</i> , <b>2008</b> , 112, 2965-2965	2.2	1
223	Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. <i>Blood</i> , <b>2009</b> , 114, 825-825	2.2	1
222	FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype. <i>Blood</i> , <b>2010</b> , 116, 1719-1719	2.2	1
221	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 88	7	1
220	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. <i>Haematologica</i> , <b>2021</b> , 106, 2986-2989	6.6	1
219	Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry. <i>Leukemia</i> , <b>2021</b> , 35, 3021-3025	10.7	1
218	Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 635-640	4.4	1

217	Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 539-548	6.1	1
216	Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML). <i>Leukemia</i> , <b>2020</b> , 34, 630-634	10.7	1
215	A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. <i>Leukemia</i> , <b>2021</b> , 35, 1763-1772	10.7	1
214	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , <b>2021</b> , 96, 40-50	7.1	1
213	Diagnostik und Management des myelodysplastischen Syndroms. <i>Onkologe</i> , <b>2019</b> , 25, 994-1003	0.1	0
212	The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q. <i>Blood</i> , <b>2018</b> , 132, 4360-4360	2.2	0
211	Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct: Risk Factor Analysis by the German Stem Cell Registry (DRST).. <i>Blood</i> , <b>2009</b> , 114, 3328-3328	2.2	0
210	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , <b>2015</b> , 126, 3818-3818	2.2	0
209	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. <i>Blood</i> , <b>2021</b> , 138, 1745-1745	2.2	0
208	Retrospective Comparison between 12-Gray and 8-Gray Total Body Irradiation (TBI) before Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Lymphoblastic Leukemia in First Complete Remission. <i>Blood</i> , <b>2021</b> , 138, 1783-1783	2.2	0
207	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. <i>Blood</i> , <b>2021</b> , 138, 692-692	2.2	0
206	Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status. <i>Blood</i> , <b>2021</b> , 138, 2380-2380	2.2	0
205	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. <i>Blood</i> , <b>2021</b> , 138, 2920-2920	2.2	0
204	Frequency and Clinical Characteristics Associated with Putative CAR Targets ADGRE2, CCR1, CD70, and LILRB2 in Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 5259-5259	2.2	0
203	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML. <i>Blood</i> , <b>2019</b> , 134, 2545-2545	2.2	0
202	NF1 Alterations Are Common In AML with Complex Karyotype and Correlate with Specific Genomic Imbalances. <i>Blood</i> , <b>2010</b> , 116, 4179-4179	2.2	0
201	Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients. <i>Blood</i> , <b>2012</b> , 120, 1402-1402	2.2	0
200	Histiocytic sarcoma progressing from follicular lymphoma and mimicking acquired hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2441-2443	3	0

199	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E207-E210	7.1	o
198	Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 399-409	1.9	o
197	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 481-491	4.4	o
196	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2742-2748	4.4	o
195	Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. <i>Blood Advances</i> , <b>2021</b> , 5, 4485-4499	7.8	o
194	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. <i>Journal of Medical Genetics</i> , <b>2017</b> , 54, 640-650	5.8	
193	Addition of in-vitro generated endothelial microparticles to von-Willebrand plasma improves primary and secondary hemostasis. <i>Thrombosis Research</i> , <b>2014</b> , 133, 445-50	8.2	
192	Individualisierte Medizin in der Diagnostik und prognostischen Einschätzung in der akuten myeloischen Leukämie mit normalem Karyotyp bei Erwachsenen unter 65 Jahren: eine systematische Literaturrecherche und Metaanalyse zu FLT3-ITD. <i>Ethik in Der Medizin</i> , <b>2013</b> , 25, 183-193	0.5	
191	Hematopoietic growth factors--present status and future development. <i>Seminars in Hematology</i> , <b>2007</b> , 44, 131-2	4	
190	Bendamustine. <i>Drugs</i> , <b>2001</b> , 61, 639-640	12.1	
189	Stem cell mobilization in normal donors. <i>Stem Cells and Development</i> , <b>1998</b> , 7, 5-7		
188	IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML. <i>Blood</i> , <b>2020</b> , 136, 32-33	2.2	
187	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. <i>Blood</i> , <b>2020</b> , 136, 9-10	2.2	
186	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). <i>Blood</i> , <b>2020</b> , 136, 42-42	2.2	
185	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , <b>2020</b> , 136, 3-4	2.2	
184	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). <i>Blood</i> , <b>2021</b> , 138, 3959-3959	2.2	
183	Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy. <i>Blood</i> , <b>2021</b> , 138, 2369-2369	2.2	
182	Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2021</b> , 138, 611-611	2.2	

- 181 Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). *Blood*, **2021**, 138, 3952-3952 2.2
- 180 Priming with Granulocyte Colony-Stimulating Factor (G-CSF) Has No Impact on Treatment Outcome but Impairs Mobilization of Peripheral Blood Stem Cells (PBSC) in Elderly Patients with Acute Myeloid Leukemia: Results of a Randomized Oligocenter Trial.. *Blood*, **2004**, 104, 867-867 2.2
- 179 Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells.. *Blood*, **2004**, 104, 2024-2024 2.2
- 178 Analysis of Vector Integration with LM-PCR after Retroviral HSV-Tk/ $\beta$ Gal Gene Transfer.. *Blood*, **2004**, 104, 1752-1752 2.2
- 177 Prospective Evaluation of a GvHD-Specific Proteom Pattern.. *Blood*, **2004**, 104, 728-728 2.2
- 176 Thromboelastometry in Patients Receiving Platelet Transfusion after Chemotherapy.. *Blood*, **2004**, 104, 3630-3630 2.2
- 175 Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol- $\beta$  *Blood*, **2004**, 104, 4729-4729 2.2
- 174 Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.. *Blood*, **2004**, 104, 2896-2896 2.2
- 173 Differential Sensitivity of Normal and CML-Derived CD34+ Cells to Inhibition of SHP-2 Gene Expression by RNA Interference (RNAi).. *Blood*, **2004**, 104, 2778-2778 2.2
- 172 Decrease of Malignant Potential of t(8;21) Positive Cells after Stable Expression of RUNX-CBFA2T1-Specific Small Interfering RNA.. *Blood*, **2004**, 104, 4274-4274 2.2
- 171 Marrow Fibrosis in Myelodysplastic Syndromes - Its Significance in the Context of the WHO Classification of Disease and the International Prognostic Scoring System.. *Blood*, **2004**, 104, 1446-1446 2.2
- 170 Targeting RAS Signaling in Multiple Myeloma (MM): Synergistic Inhibition by Co-Treatment with the MEK Inhibitor U0126 and Prenylation Inhibitors.. *Blood*, **2004**, 104, 3398-3398 2.2
- 169 MN1 Expression Predicts Prognosis of Acute Myeloid Leukemia with Normal Cytogenetics.. *Blood*, **2005**, 106, 2351-2351 2.2
- 168 Isolation of Cytomegalovirus (CMV) Specific T-Cells from Sersopositive Donors: A Possible Tool for CMV-Prophylaxis.. *Blood*, **2005**, 106, 3037-3037 2.2
- 167 Prenylation Inhibitors Block IL-6 and IGF-1 Dependent Activation of RAS Signaling in Multiple Myeloma Cells.. *Blood*, **2005**, 106, 3373-3373 2.2
- 166 Pooled Data Analysis of Acute Myeloid Leukemia Patients  $\geq$  60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.. *Blood*, **2005**, 106, 2374-2374 2.2
- 165 Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.. *Blood*, **2005**, 106, 747-747 2.2
- 164 Prospective Evaluation of Graft-Versus-Host Disease-Specific Proteomics Pattern in Patients after Allogeneic Stem Cell Transplantation.. *Blood*, **2005**, 106, 3093-3093 2.2

- 163 All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. *Blood*, **2005**, 106, 1849-1849 2.2
- 162 Atypical Presentations of EBV Reactivation and EBV-Associated PTLD Post-HSCT: Implication for Routine EBV Surveillance after Allogeneic HSCT?.. *Blood*, **2005**, 106, 5364-5364 2.2
- 161 Regulation of T Cell Homeostasis and Cell Cycling in Patients with Acute Myeloid Leukemia.. *Blood*, **2005**, 106, 2767-2767 2.2
- 160 Reduced Binding of C/EBP $\beta$  to Myeloid Specific Promoters with Altered Gene Expression in the Presence of PML/RAR $\alpha$  *Blood*, **2005**, 106, 2999-2999 2.2
- 159 Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response.. *Blood*, **2005**, 106, 1106-1106 2.2
- 158 Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).. *Blood*, **2005**, 106, 1138-1138 2.2
- 157 Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients  $\geq$  0 Years with Standard Risk AML.. *Blood*, **2005**, 106, 151-151 2.2
- 156 Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.. *Blood*, **2005**, 106, 2352-2352 2.2
- 155 All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. *Blood*, **2006**, 108, 1949-1949 2.2
- 154 Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients  $\geq$  0 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. *Blood*, **2006**, 108, 607-607 2.2
- 153 Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, TrkA.. *Blood*, **2006**, 108, 1442-1442 2.2
- 152 Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients - A Single Center Study.. *Blood*, **2006**, 108, 3030-3030 2.2
- 151 Diagnostic Workup of Patients with Acquired Von Willebrand Syndrome.. *Blood*, **2006**, 108, 1045-1045 2.2
- 150 Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission.. *Blood*, **2006**, 108, 3141-3141 2.2
- 149 Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.. *Blood*, **2006**, 108, 1439-1439 2.2
- 148 Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 3485-3485 2.2
- 147 An Ex Vivo Perfusion Model To Study the Treatment of Thrombotic Microangiopathy during Pig-to-Human Xenogenic Kidney Transplantation.. *Blood*, **2007**, 110, 3190-3190 2.2
- 146 FLAMSA Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in High Risk Myeloid Malignancies Is Also Feasible with Partially Mismatched Donors.. *Blood*, **2007**, 110, 3068-3068 2.2



145	Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.. <i>Blood</i> , <b>2007</b> , 110, 1836-1836	2.2
144	Specific miRNA Silencing by Lentivirus Mediated Antagomir Expression in Chronic Myeloid Leukemia (CML) Cells.. <i>Blood</i> , <b>2007</b> , 110, 1017-1017	2.2
143	Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).. <i>Blood</i> , <b>2007</b> , 110, 762-762	2.2
142	Potential of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.. <i>Blood</i> , <b>2007</b> , 110, 3479-3479	2.2
141	Neurotrophin Receptors and Ligands Are Highly Expressed in Acute Leukemia and Promote Leukemogenesis.. <i>Blood</i> , <b>2007</b> , 110, 696-696	2.2
140	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.. <i>Blood</i> , <b>2007</b> , 110, 1837-1837	2.2
139	The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.. <i>Blood</i> , <b>2007</b> , 110, 881-881	2.2
138	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. <i>Blood</i> , <b>2017</b> , 130, 907-907	2.2
137	Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4581-4581	2.2
136	Synergy between FLT3-ITD and p53 Haploinsufficiency or Loss in the Development of Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 771-771	2.2
135	Outcome of Transformed Fanconi Anaemia Patients after Hematopoietic Stem Cell Transplantation: Analysis on Behalf of European Group for Blood and Marrow Transplantation. <i>Blood</i> , <b>2018</b> , 132, 646-646	2.2
134	Prognostic Value of Cpss Cytogenetic Risk Classification in Patients with CMML after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , <b>2018</b> , 132, 2182-2182	2.2
133	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study By the EBMT Chronic Malignancies Working Party. <i>Blood</i> , <b>2018</b> , 132, 3465-3465	2.2
132	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. <i>Blood</i> , <b>2018</b> , 132, 4025-4025	2.2
131	T Regulatory Cell Receptor Repertoire Focusing and Clonal Expansion Indicates Control of Acute GvHD after Donor Lymphocyte Infusion. <i>Blood</i> , <b>2018</b> , 132, 822-822	2.2
130	Focused Regulatory T Cell Repertoires Are Indicative of Successful GvHD Control in Experimental and Clinical Stem Cell Transplantation. <i>Blood</i> , <b>2018</b> , 132, 2029-2029	2.2
129	NKG2C+CD57+ Natural Killer Cells May Play an Important Role in Maintaining Virus-Specific Immune Reconstitution Post-Allogeneic HSCT. <i>Blood</i> , <b>2018</b> , 132, 3327-3327	2.2
128	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2018</b> , 132, 1016-1016	2.2

- 127 CAR-T Cells Targeting gp350 Recognize Immortalized Cells Latently Infected with EBV. *Blood*, **2018**, 132, 4540-4540 2.2
- 126 Haploidentical Transplantation Using High Dose Post-Transplant Cyclophosphamide for Patients with Aplastic Anemia : The European Group for Blood and Marrow Transplantation Experience. *Blood*, **2018**, 132, 486-486 2.2
- 125 Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate. *Blood*, **2018**, 132, 2617-2617 2.2
- 124 In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?. *Blood*, **2018**, 132, 3892-3892 2.2
- 123 Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. *Blood*, **2018**, 132, 1533-1533 2.2
- 122 Functional Screening for Pathways Regulating Chemoresistance and Sensitivity in Leukemia Stem Cells. *Blood*, **2018**, 132, 3933-3933 2.2
- 121 The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT. *Blood*, **2018**, 132, 4639-4639 2.2
- 120 Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. *Blood*, **2018**, 132, 4390-4390 2.2
- 119 Pembrolizumab Therapy Exacerbates EBV-Induced Infections and Tumors in a Long-Term Fully Humanized Mouse Model. *Blood*, **2018**, 132, 2405-2405 2.2
- 118 Metformin treatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. *Blood*, **2018**, 132, 1532-1532 2.2
- 117 Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia. *Blood*, **2018**, 132, 759-759 2.2
- 116 Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification. *Blood*, **2018**, 132, 994-994 2.2
- 115 Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSC). *Blood*, **2019**, 134, 2740-2740 2.2
- 114 Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. *Blood*, **2019**, 134, 2719-2719 2.2
- 113 NKG2C+CD57+ Natural Killer Cells May Play an Important Role in Maintaining Virus-Specific Immune Reconstitution Post-Allogeneic HSCT. *Blood*, **2019**, 134, 1939-1939 2.2
- 112 Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. *Blood*, **2019**, 134, 45-45 2.2
- 111 MN1 Expression Is an Independent Prognostic Marker in FLT3-Mutated Acute Myeloid Leukemia and Is Involved in the Resistance to FLT3 Inhibitors. *Blood*, **2019**, 134, 1403-1403 2.2
- 110 Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 1359-1359 2.2

109	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 5166-5166	2.2
108	Efficacy of Chemotherapy, Phd-Inhibitor Molidustat or BRD4 Inhibitor JQ1 in Combination with Targeted Inhibition of Mutated IDH1 in Human AML In Vivo. <i>Blood</i> , <b>2019</b> , 134, 3933-3933	2.2
107	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e17103-e17103	2.2
106	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5084-5084	2.2
105	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , <b>2014</b> , 124, 1254-1254	2.2
104	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts . <i>Blood</i> , <b>2014</b> , 124, 2636-2636	2.2
103	Expression of the ETS Transcription Factor GABPBs Correlated to BCR-ABL/ABL ratio in Human CML and Mediates Imatinib Sensitivity. <i>Blood</i> , <b>2014</b> , 124, 1787-1787	2.2
102	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of	2.2
101	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , <b>2014</b> , 124, 1216-1216	2.2
100	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. <i>Blood</i> , <b>2014</b> , 124, 1920-1920	2.2
99	High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. <i>Blood</i> , <b>2014</b> , 124, 2304-2304	2.2
98	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. <i>Blood</i> , <b>2015</b> , 126, 224-224	2.2
97	Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes. <i>Blood</i> , <b>2015</b> , 126, 4114-4114	2.2
96	Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA. <i>Blood</i> , <b>2015</b> , 126, 1581-1581	2.2
95	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT. <i>Blood</i> , <b>2015</b> , 126, 3105-3105	2.2
94	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2015</b> , 126, 196-196	2.2
93	Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG). <i>Blood</i> , <b>2015</b> , 126, 227-227	2.2
92	The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFβ-MYH11. <i>Blood</i> , <b>2015</b> , 126, 1383-1383	2.2

- 91 Patient Derived Xenotransplantation Model of Atypical Chronic Myeloid Leukemia (aCML). *Blood*, **2015**, 126, 2836-2836 2.2
- 90 Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA). *Blood*, **2016**, 128, 4038-4038 2.2
- 89 Stable Silencing of RUNX1/ETO Induces Expression of a Shortened PU.1 Variant in t(8;21) Kasumi Cells. *Blood*, **2016**, 128, 2716-2716 2.2
- 88 Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. *Blood*, **2016**, 128, 522-522 2.2
- 87 Genetic Profile of Acute Erythroid Leukemia. *Blood*, **2016**, 128, 40-40 2.2
- 86 Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies. *Blood*, **2008**, 112, 344-344 2.2
- 85 Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.. *Blood*, **2008**, 112, 3259-3259 2.2
- 84 Trans-Atlantic Consensus on the Medical Management of Radiation Accident Victims. *Blood*, **2008**, 112, 2361-2361 2.2
- 83 Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. *Blood*, **2008**, 112, 2514-2514 2.2
- 82 Lineage-Specific Regulation of miRNA-Expression by the BCR-ABL Oncogene.. *Blood*, **2008**, 112, 1084-1084 2.2
- 81 Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG). *Blood*, **2008**, 112, 699-699 2.2
- 80 Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. *Blood*, **2009**, 114, 578-578 2.2
- 79 Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients.. *Blood*, **2009**, 114, 3388-3388 2.2
- 78 Tissue-Factor- and PSGL-1-Bearing Microparticles Are Strong Outcome Predictors in Allogeneic Stem Cell Transplantation.. *Blood*, **2009**, 114, 2263-2263 2.2
- 77 Prospective Evaluation of An Agvhd-Specific Proteomic Pattern in More Than 340 Patients.. *Blood*, **2009**, 114, 347-347 2.2
- 76 High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.. *Blood*, **2009**, 114, 582-582 2.2
- 75 Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. *Blood*, **2009**, 114, 2621-2621 2.2
- 74 Human Development Index Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia.. *Blood*, **2009**, 114, 1193-1193 2.2

73	Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).. <i>Blood</i> , <b>2009</b> , 114, 1586-1586	2.2
72	Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.. <i>Blood</i> , <b>2009</b> , 114, 2960-2960	2.2
71	Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.. <i>Blood</i> , <b>2009</b> , 114, 1622-1622	2.2
70	A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.. <i>Blood</i> , <b>2009</b> , 114, 3761-3761	2.2
69	Mobilized Peripheral Blood Stem Cells (PBSC) Compared with Bone Marrow (BM) as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning (RIC-alloSCT) in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR): a Retrospective Analysis From the ALWP of EBMT.. <i>Blood</i> , <b>2009</b> , 114, 527-527	2.2
68	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. <i>Blood</i> , <b>2009</b> , 114, 2613-2613	2.2
67	Prospective Evaluation of Proteomic Screening with An Agvhd-Specific Proteomic Pattern MS-17.. <i>Blood</i> , <b>2009</b> , 114, 2246-2246	2.2
66	Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation.. <i>Blood</i> , <b>2009</b> , 114, 1209-1209	2.2
65	Proteomic Screening Applied to the Diagnosis of Chronic Graft-Versus-Host-Disease.. <i>Blood</i> , <b>2009</b> , 114, 1164-1164	2.2
64	Functional Role of BAALC In Leukemogenesis. <i>Blood</i> , <b>2010</b> , 116, 4194-4194	2.2
63	Enforced Expression of Mir-125b Blocks Granulocytic Differentiation by Simultaneous Repression of Multiple Targets.. <i>Blood</i> , <b>2010</b> , 116, 1554-1554	2.2
62	Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial. <i>Blood</i> , <b>2010</b> , 116, 2185-2185	2.2
61	Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSG Phase III Trial. <i>Blood</i> , <b>2010</b> , 116, 4024-4024	2.2
60	Tregs In Graft-Versus-Host Disease: A Task Force In Trouble?.. <i>Blood</i> , <b>2010</b> , 116, 3748-3748	2.2
59	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. <i>Blood</i> , <b>2010</b> , 116, 849-849	2.2
58	Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup. <i>Blood</i> , <b>2010</b> , 116, 2175-2175	2.2
57	Virus-Associated Hemophagocytic Syndrome Contributes to Fatal Outcome In Critical Ill Patients with 2009 Influenza A (H1N1) Infection.. <i>Blood</i> , <b>2010</b> , 116, 3795-3795	2.2
56	Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification. <i>Blood</i> , <b>2010</b> , 116, 1693-1693	2.2

- 55 Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells. *Blood*, **2011**, 118, 1418-1418 2.2
- 54 Regulatory T Cells of G-CSF Mobilized Stem Cell Donors Qualify for Clinical Applications,. *Blood*, **2011**, 118, 4055-4055 2.2
- 53 Endothelial Microparticles Improve Primary and Secondary Hemostasis in Patients with Von-Willebrand Disease. *Blood*, **2011**, 118, 2287-2287 2.2
- 52 The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients. *Blood*, **2011**, 118, 1734-1734 2.2
- 51 Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine. *Blood*, **2011**, 118, 2609-2609 2.2
- 50 ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,. *Blood*, **2011**, 118, 3554-3554 2.2
- 49 Prevalence and Clinical Effect of TET2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). *Blood*, **2011**, 118, 1448-1448 2.2
- 48 Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples. *Blood*, **2011**, 118, 237-237 2.2
- 47 Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,. *Blood*, **2011**, 118, 3548-3548 2.2
- 46 Function of STAT5 Isoforms in Bcr-Abl Positive Cells. *Blood*, **2011**, 118, 1313-1313 2.2
- 45 FLT3-ITD-Associated Accumulation of Dendritic Cell Precursors, Depletion of Mature Dendritic Cells and Abnormal Cytokine Production in Acute Myeloid Leukemia: Analyses At Diagnosis, Remission and Relapse. *Blood*, **2011**, 118, 2525-2525 2.2
- 44 Monocytes Induced to Differentiate Into Dendritic Cells After Overnight Transduction with Lentiviral Vectors Co-Expressing GM-CSF/ IL-4 and a Truncated Form of WT1: Preclinical Validation for Immunotherapy of High Risk Leukemia Patients After Allo-SCT. *Blood*, **2011**, 118, 2981-2981 2.2
- 43 Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse. *Blood*, **2011**, 118, 250-250 2.2
- 42 Role of IL-15 in the Stimulation of Human CD8+ CMV-Reactive Human T Cells in a Hu-PBL Mouse Model Preconditioned with Self-Differentiated Human Dendritic Cells Programmed with Lentiviral Vectors. *Blood*, **2011**, 118, 2966-2966 2.2
- 41 Prognostic Significance and Target Potential of Axl in Acute Myeloid Leukemia. *Blood*, **2011**, 118, 940-940 2.2
- 40 Persistence of Recipient-Derived Antiviral T cells Severely Influence Donor Chimerism Post Allogeneic HSCT,. *Blood*, **2011**, 118, 3240-3240 2.2
- 39 Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. *Blood*, **2011**, 118, 1441-1441 2.2
- 38 Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study. *Blood*, **2011**, 118, 1344-1344 2.2

37	Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , <b>2011</b> , 118, 3004-3004	2.2
36	Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS. <i>Blood</i> , <b>2011</b> , 118, 4128-4128	2.2
35	Sequential Chemotherapy Followed by Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , <b>2012</b> , 120, 2025-2025	2.2
34	Routes of Clonal Evolution Into Complex Karyotypes in Myelodysplastic Syndrome Patients with Del(5q). <i>Blood</i> , <b>2012</b> , 120, 522-522	2.2
33	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. <i>Blood</i> , <b>2012</b> , 120, 3801-3801	2.2
32	NADH Dehydrogenase Subunit 4 (ND4) Mutations in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , <b>2012</b> , 120, 1380-1380	2.2
31	Aberrant Expression of the MLL5, BAALC, ID1, and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , <b>2012</b> , 120, 1407-1407	2.2
30	Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts. <i>Blood</i> , <b>2012</b> , 120, 3748-3748	2.2
29	Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis. <i>Blood</i> , <b>2012</b> , 120, 1740-1740	2.2
28	Investigation of Urine/Plasma Biomarkers to Predict Tolerance and Graft-Versus-Host Disease Post Allogeneic Stem Cell Transplantation. <i>Blood</i> , <b>2012</b> , 120, 3049-3049	2.2
27	High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , <b>2012</b> , 120, 3148-3148	2.2
26	Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011. <i>Blood</i> , <b>2012</b> , 120, 2804-2804	2.2
25	Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. <i>Blood</i> , <b>2012</b> , 120, 785-785	2.2
24	Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis. <i>Blood</i> , <b>2012</b> , 120, 770-770	2.2
23	Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy. <i>Blood</i> , <b>2012</b> , 120, 3110-3110	2.2
22	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 152-152	2.2
21	Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC). <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e16064-e16064	2.2
20	Genetic Characterization Of Aplastic Anemia Patients By Targeted Sequencing. <i>Blood</i> , <b>2013</b> , 122, 2470-2470	2.2

19	Prognostic Impact Of a Newly Defined Structurally Complex Karyotype In Patients With AML and MDS After Allogeneic Stem Cell Transplantation. <i>Blood</i> , <b>2013</b> , 122, 3362-3362	2.2
18	Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML. <i>Blood</i> , <b>2013</b> , 122, 2804-2804	2.2
17	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , <b>2013</b> , 122, 2555-2555	2.2
16	Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 830-830	2.2
15	Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , <b>2013</b> , 122, 3878-3878	2.2
14	An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1. <i>Blood</i> , <b>2013</b> , 122, 2593-2593	2.2
13	Prognostic Value Of Plasma Biomarkers Compared To Urinary Proteome Patterns. <i>Blood</i> , <b>2013</b> , 122, 4593-4593	2.2
12	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). <i>Blood</i> , <b>2013</b> , 122, 1332-1332	2.2
11	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. <i>Blood</i> , <b>2013</b> , 122, 2753-2753	2.2
10	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 1314-1314	2.2
9	Mir~17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835	2.2
8	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , <b>2013</b> , 122, 2586-2586	2.2
7	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. <i>Blood</i> , <b>2013</b> , 122, 2759-2759	2.2
6	Graft Versus Leukemia With Little Graft Versus Host Disease? Long Term Follow-Up Of a Study Using Transduced Donor T-Cells For Donor Leukocyte Transfusion. <i>Blood</i> , <b>2013</b> , 122, 4207-4207	2.2
5	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 523-523	2.2
4	MP475OXALIPLATIN PHARMACOKINETICS ON HEMODIALYSIS IN A PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, i499-i499	4.3
3	Donor-derived IL-17A and IL-17F deficiency triggers Th1 allo-responses and increases gut leakage during acute GVHD. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231222	3.7
2	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 16457	4.9



- 1 Long-term bone marrow culture data is the most powerful predictor for peripheral blood progenitor cell mobilization in healthy donors. *Haematologica*, **2005**, 90, 294 6.6